Current Limitations of CAR T-Cell Therapy in Multiple Myeloma: Muhamed Baljevic, MD
The assistant professor from University of Nebraska Medical Center discussed the current limitations of CAR T-cell therapy in multiple myeloma.
This content originally appeared on our sister site, OncLive.
OncLive spoke with Muhamed Baljevic, MD, assistant professor, Department of Internal Medicine, Division of Oncology and Hematology, College of Medicine, University of Nebraska Medical Center, to learn more about the current limitations of CAR T-cell therapy in multiple myeloma.
Baljevic discussed clinical trials evaluating CAR T-cell therapy in multiple myeloma in which some patients who underwent apheresis and CAR T-cell collection were unable to receive the treatment because their disease was too aggressive and dynamic. Even with bridging therapy, these patients were unable to wait the 4 to 5 weeks required to generate the CAR T-cell therapy.
Additionally, a significantly number of patients were not referred for CAR T-cell therapy because they lived too far away from an academic center that offers the treatment, Baljevic explains. These patients, as well as older patients and those with poor performance statuses, represent a population with unmet need for CAR T-cell therapy in multiple myeloma.
However, emerging constructs that have been optimized to be potentially safer and more effective could have clinical utility in these patient populations, Baljevic concludes.
